Table 5.

Summary of logistic regression analysis for reporting feasibility indicators and other related characteristics in studies considered Never Citers, Indirect Citers, and Citers (N = 367)

Feasibility-related reporting characteristics	Indirect Citersa			Citersa
	N = 71			N = 167
	Odds ratio	95% CIb	p-value	Odds ratio	95% CIb	p-value
Feasibility indicators
Recruitment	0.83	0.44–1.54	0.544	1.78	0.97–3.28	0.065
Retention	1.58	0.84–2.96	0.155	3.75	1.98–7.13	< 0.001
Acceptability	2.39	1.29–4.45	0.006	14.15	6.43–31.15	< 0.001
Adverse events	1.36	0.52–3.55	0.531	4.38	2.07–9.23	< 0.001
Attendance	1.51	0.70–3.25	0.293	1.39	0.69–2.79	0.358
Compliance	1.35	0.74–2.46	0.330	2.62	1.55–4.45	< 0.001
Cost	0.91	0.22–3.73	0.891	4.35	1.66–11.40	0.003
Data collection	1.01	0.33–3.14	0.984	4.35	1.93–9.78	< 0.001
Treatment fidelity	2.12	1.05–4.29	0.036	8.82	4.73–16.44	< 0.001
Feasibility-related characteristics
Title includes feasibility-related language	0.72	0.39–.34	0.303	1.51	0.82–2.78	0.188
Feasibility mentioned in purpose statement	1.36	0.75–2.48	0.314	9.87	4.58–21.23	< 0.001
Efficacy mentioned in purpose statement	0.77	0.43–1.38	0.379	0.54	0.32–0.91	0.020
Progression criteria provided	1.86	0.26–13.51	0.539	17.04	3.91–74.29	< 0.001
Statistical testing for efficacy	0.36	0.18–0.75	0.006	0.13	0.07–0.26	< 0.001
Feasibility framed as primary outcome	1.37	0.76–2.48	0.296	9.66	4.63–20.17	< 0.001
Feasibility of the study mentioned in conclusionc	1.95	0.95–4.03	0.070	6.31	2.43–16.36	< 0.001
Efficacy of the study mentioned in conclusionc	0.67	0.35–1.28	0.223	0.50	0.26–0.99	0.046
Caution advised regarding efficacyc	1.13	0.59–2.18	0.716	0.61	0.31–1.19	0.152
Future testing suggestedc	0.46	0.33–1.59	0.223	0.26	0.08–0.84	0.024

^aNever Citers (N = 129) is the referent group

^b95% CI stands for 95% confidence interval

^cProtocols excluded from analysis

Bold denotes significance at the p < 0.05 level